Search > Obesity
My employer runs this trial

Maridebart Cafraglutide for Obesity

(MARITIME-PEN Trial)

AC
Overseen ByAmgen Call Center
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Amgen
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.

Who Is on the Research Team?

M

MD

Principal Investigator

Amgen

Are You a Good Fit for This Trial?

This trial is for adults who are overweight or have obesity. Participants should be able to use an autoinjector at home and must not have any conditions that would prevent safe self-injection, as determined by the study team.

Inclusion Criteria

At least 1 unsuccessful attempt at weight loss by diet and exercise
I am a female and I use birth control.
Willingness to follow trial procedures for the duration of the trial
See 1 more

Exclusion Criteria

My obesity is caused by a hormone or gland disorder.
I have had or plan to have surgery or a procedure to treat obesity.
I have had chronic pancreatitis or a recent episode of acute pancreatitis.
See 5 more

What Are the Treatments Tested in This Trial?

Interventions

  • Maridebart cafraglutide

Trial Overview

The study tests whether adults with obesity or overweight can safely and effectively give themselves maridebart cafraglutide injections at home using an autoinjector device.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Maridebart cafraglutideExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Amgen

Lead Sponsor

Trials
1,508
Recruited
1,433,000+
Founded
1980
Headquarters
Thousand Oaks, USA
Known For
Human Therapeutics
Top Products
Enbrel, Prolia, Neulasta, Otezla
Robert A. Bradway profile image

Robert A. Bradway

Amgen

Chief Executive Officer since 2012

MBA from Harvard Business School

Paul Burton profile image

Paul Burton

Amgen

Chief Medical Officer since 2023

MD from University of London, PhD in Molecular and Cellular Biology from Imperial College London

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.